Brian Hubbard
Chief Executive Officer at Anji Pharmaceuticals, Inc.
Profile
Brian Hubbard is currently the Chief Executive Officer at Anji Pharmaceuticals, Inc. and a Partner at Sprout Bioventures.
He was previously the Chief Executive Officer at Dogma Therapeutics, Inc. from 2015 to 2020, Director at Novartis AG from 2002 to 2008, Director at The Broad Institute, Inc. from 2011 to 2015, and Sr. Director at Merck Global Health Innovation LLC from 2008 to 2011.
Dr. Hubbard received his undergraduate degree from The College of William & Mary in 1994, his doctorate from the University of Illinois, and his graduate degree from Harvard Medical School.
Brian Hubbard active positions
Companies | Position | Start |
---|---|---|
Sprout Bioventures
Sprout Bioventures Investment ManagersFinance Sprout Bioventures (Sprout Bioventures) is a venture capital firm founded in 1900. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 2017-12-31 |
Anji Pharmaceuticals, Inc.
Anji Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anji Pharmaceuticals, Inc. engages in discovery and development of medicines for human genetics. The company is headquartered in Cambridge, MA. | Chief Executive Officer | 2018-01-31 |
Former positions of Brian Hubbard
Companies | Position | End |
---|---|---|
Dogma Therapeutics, Inc.
Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dogma Therapeutics, Inc. developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease. The company is headquartered in Boxford, MA. | Chief Executive Officer | 2020-08-01 |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Director of Research - Equity | 2015-08-01 |
Merck Global Health Innovation LLC
Merck Global Health Innovation LLC Investment ManagersFinance Merck Global Health Innovation LLC (Merck Global Health) is a venture capital subsidiary of Merck & co Inc founded in 2010. The firm is headquartered in White house station, New Jersey. | Director of Research - Equity | 2011-09-01 |
NOVARTIS AG | Director of Research - Equity | 2008-01-01 |
Training of Brian Hubbard
The College of William & Mary | Undergraduate Degree |
University of Illinois | Doctorate Degree |
Harvard Medical School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
NOVARTIS AG | Health Technology |
Private companies | 5 |
---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Merck Global Health Innovation LLC
Merck Global Health Innovation LLC Investment ManagersFinance Merck Global Health Innovation LLC (Merck Global Health) is a venture capital subsidiary of Merck & co Inc founded in 2010. The firm is headquartered in White house station, New Jersey. | Finance |
Sprout Bioventures
Sprout Bioventures Investment ManagersFinance Sprout Bioventures (Sprout Bioventures) is a venture capital firm founded in 1900. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Anji Pharmaceuticals, Inc.
Anji Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anji Pharmaceuticals, Inc. engages in discovery and development of medicines for human genetics. The company is headquartered in Cambridge, MA. | Health Technology |
Dogma Therapeutics, Inc.
Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dogma Therapeutics, Inc. developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease. The company is headquartered in Boxford, MA. | Health Technology |
- Stock Market
- Insiders
- Brian Hubbard